Company Overview and News

 
Marenica Energy’s process testwork indicates high uranium recovery

2018-02-08 proactiveinvestors.com.au
Marenica Energy Ltd’s (ASX:MEY) testwork has confirmed the benefits of its proprietary U-pgrade process on the ore samples collected from the Langer Heinrich uranium mine in Namibia.

 
Marenica Energy to lift cash position

2017-04-06 proactiveinvestors.com.au
Marenica Energy (ASX:MEY) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Deep Yellow boosts size and quality of Namibian uranium project

2016-10-12 proactiveinvestors.com.au
Deep Yellow Ltd (ASX:DYL) has increased the metal content by 12% at its Tumas uranium project located in Namibia.

 
Deep Yellow Ltd's Greg Cochran talks uranium at Proactive's Spotlight CEO Sessions

2016-10-07 proactiveinvestors.com.au
Deep Yellow Ltd's (ASX:DYL) managing director, Greg Cochran, joined the Proactive Investors Spotlight CEO Roadshow in Sydney and Melbourne this week, providing investors with the latest update on the company. The company positioning itself to be the next uranium mine to be developed in the country. DYL has also executed an agreement with Marenica Energy Ltd (ASX:MEY) for the use of that company’s proprietary, ground breaking processing technology called U-pgrade™.

 
Deep Yellow Ltd's Greg Cochran talks uranium at Proactive's Spotlight CEO Sessions

2016-10-07 proactiveinvestors.com.au
Deep Yellow Ltd's (ASX:DYL) managing director, Greg Cochran, joined the Proactive Investors Spotlight CEO Roadshow in Sydney and Melbourne this week, providing investors with the latest update on the company. The company positioning itself to be the next uranium mine to be developed in the country. DYL has also executed an agreement with Marenica Energy Ltd (ASX:MEY) for the use of that company’s proprietary, ground breaking processing technology called U-pgrade™.

 
Deep Yellow Ltd brings Tumas uranium to Proactive's CEO Spotlight Sessions

2016-09-29 proactiveinvestors.com.au
Deep Yellow Ltd (ASX:DYL) is an advanced stage uranium explorer with a focus on its Tumas Project in Namibia. The company positioning itself to be the next uranium mine to be developed in the country. DYL has also executed an agreement with Marenica Energy (ASX:MEY) for the use of that company’s proprietary, ground breaking processing technology called U-pgradeTM. Find out more from Greg Cochran, managing director, at Proactive's Spotlight CEO Sessions in Sydney and Melbourne in October 2016.

 
Deep Yellow Ltd to use advanced technology to process Namibian uranium

2016-09-12 proactiveinvestors.com.au
Deep Yellow Ltd (ASX:DYL) has executed a technology licence agreement for the application of Marenica Energy Ltd’s (ASX:MEY) U-pgrade process on the company’s Tumas Project in Namibia. The commercialisation agreement follows the recent conclusion of a successful metallurgical testwork program and aims to share the economic benefit of the resource/technology combination. The testwork program demonstrated that processing Tumas ore through the U-pgrade process has the potential to reject up to 98% of the mass whilst recovering over 82% of the uranium.

 
Deep Yellow Ltd on track to process Namibian uranium using new technology

2016-05-20 proactiveinvestors.com.au
Deep Yellow Ltd (ASX:DYL) has received successful interim results from the metallurgical testwork program currently underway on bulk samples from the company’s Tumas Project located in Namibia. The tests have demonstrated that by using Marenica Energy Ltd’s (ASX:MEY) U-pgrade process, a high uranium recovery, low mass, high grade uranium concentrate can be produced from the Tumas resource. The tests, which are being conducted at the CSIRO and Nagrom Laboratories in Perth, are on track to be completed by mid-year.

 
 
Change of Registered Office

2016-05-02 asx.com.au

 
 
Change in substantial holding

2016-04-28 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...